| ₹ crore | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue | 929 | 738 | +25.9% |
| EBITDA | 192 | 72.0 | +166.7% |
| EBITDA margin | 20.7% | 9.8% | +10.9 pts |
| Profit before tax | 116 | −109 | — |
| Net profit | 107 | −108 | — |
| EPS | ₹6.55 | −₹5.53 | — |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 30,997 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 629 | 629 | 534 | 505 | 90.0 | ||
| 341 | 341 | 304 | 303 | 308 | ||
| 2,125 | 2,125 | 1,859 | 2,112 | 1,887 | ||
| 32,834 | — | — | — | — | ||
| 3,564 | 3,373 | 3,012 | 2,798 | 2,651 | ||
| — | +12.0% | +7.6% | +5.5% | — | ||
| 772 | 652 | 393 | 39.0 | 101 | ||
| 21.7% | 19.3% | 13.1% | 1.4% | 3.8% | ||
| 546 | 425 | 176 | −184 | −150 | ||
| 414 | 199 | −57.0 | −472 | −621 | ||
| 11.6% | 5.9% | −1.9% | −16.9% | −23.4% | ||
| ₹25.25 | ₹13.15 | −₹2.90 | −₹28.58 | −₹34.51 | ||
| — | +553.2% | +89.8% | +17.2% | — | ||
| — | 390 | −22.0 | 219 | 153 | ||
| — | −136 | −94.0 | −59.0 | −42.0 | ||
| 254 | 254 | −116 | 160 | 111 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 30,997.1 | |
| - Cash, Equiv & ST Investments | 90.0 | 505.0 | 534.0 | 629.0 | 629.0 | |
| + Minority Interest | 308.0 | 303.0 | 304.0 | 341.0 | 341.0 | |
| + Total Debt | 1,887.0 | 2,112.0 | 1,859.0 | 2,125.0 | 2,125.0 | |
| Enterprise Value | — | — | — | — | 32,834.1 | |
| Revenue | 2,651.0 | 2,798.0 | 3,012.0 | 3,373.0 | 3,564.0 | |
| Growth %, YoY | — | +5.5 | +7.6 | +12.0 | — | |
| EBITDA | 101.0 | 39.0 | 393.0 | 652.0 | 772.0 | |
| Margin % | 3.81 | 1.39 | 13.05 | 19.33 | 21.66 | |
| EBIT | -150.0 | -184.0 | 176.0 | 425.0 | 546.0 | |
| Net Income | -621.0 | -472.0 | -57.0 | 199.0 | 414.0 | |
| Margin % | -23.43 | -16.87 | -1.89 | 5.90 | 11.62 | |
| EPS, Adj (current shares) | -34.51 | -28.58 | -2.90 | 13.15 | 25.25 | |
| Growth %, YoY | — | +17.2 | +89.8 | +553.2 | — | |
| Cash from Operations | 153.0 | 219.0 | -22.0 | 390.0 | — | |
| Capital Expenditures | -42.0 | -59.0 | -94.0 | -136.0 | — | |
| Free Cash Flow | 111.0 | 160.0 | -116.0 | 254.0 | 254.0 | |
Prices at the 29 October 2026 close · figures from the company's filings with NSE
Wockhardt (NSE: WOCKPHARMA) had a market capitalisation of ₹31,151 crore at the 29 October 2026 close (₹1,922.90 a share), a PE ratio of 76.2 on the last four quarters' profit and a price-to-book ratio of 6.31. In FY26 its consolidated net profit attributable to shareholders was ₹213 crore on revenue of ₹3,373 crore; in Q1 FY27 (April–June 2026) it was ₹106 crore. Its debt-to-equity ratio was 0.40 on 31 March 2026. Promoters held 49.32% of the shares on 30 September 2026.
Wockhardt's PE ratio is 76.2 at the 29 October 2026 close (₹1,922.90 a share): a market capitalisation of ₹31,151 crore divided by consolidated net profit attributable to shareholders of ₹409 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹213 crore) it is 146.2.
Wockhardt's price-to-book (PB) ratio is 6.31 at the 29 October 2026 close: a market capitalisation of ₹31,151 crore divided by shareholders' equity (book value) of ₹4,940 crore on 31 March 2026. That is a book value of ₹304.94 per share against a share price of ₹1,922.90.
Wockhardt's net worth — shareholders' equity in its consolidated balance sheet — was ₹4,940 crore on 31 March 2026, up 13.5% from ₹4,353 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹31,151 crore at the 29 October 2026 close.
Wockhardt's market capitalisation was ₹31,151 crore at the 29 October 2026 close: 16.2 crore shares at ₹1,922.90 each.
No. Wockhardt had borrowings of ₹2,125 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.40. Its cash and current investments were ₹662 crore, so its net debt was ₹1,463 crore.
Wockhardt's basic earnings per share (EPS) were ₹13.12 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹25.20.
Wockhardt's debt-to-equity ratio was 0.40 on 31 March 2026: borrowings of ₹2,125 crore against total equity of ₹5,281 crore. A year earlier, on 31 March 2025, it was 0.40.
Wockhardt's book value per share was ₹304.94 on 31 March 2026: shareholders' equity of ₹4,940 crore divided by the 16.2 crore shares in issue, up 13.5% from ₹268.70 a year earlier. The share price at the 29 October 2026 close was ₹1,922.90.
In FY26, Wockhardt generated ₹390 crore of cash from operations and spent ₹136 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹254 crore. In FY25 it was −₹116 crore.
In FY26, Wockhardt's return on equity (ROE) was 4.6% and its return on capital employed (ROCE) was 6.5%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −1.2% and ROCE 3.2%.
On 30 September 2026, Wockhardt's shares were held by promoters 49.32%, foreign portfolio investors (FII/FPI) 7.02%, domestic institutions (DII) 9.00% (including mutual funds at 5.99%) and retail and other non-institutional investors 34.64%. Over the year, FII holding was down 0.08 percentage points from 7.10% and DII holding was down 2.01 percentage points from 11.01%.
Wockhardt's latest results are for Q1 FY27 (April–June 2026), filed on 10 August 2026: consolidated net profit attributable to shareholders ₹106 crore, against a loss of ₹90 crore in Q1 FY26; revenue from operations ₹929 crore, up 25.9% year on year.
Promoters held 49.32% of Wockhardt on 30 September 2026, up 0.24 percentage points from 49.08% the previous quarter and up 0.24 percentage points from 49.08% a year earlier, according to the shareholding pattern filed with NSE.
In FY26 (April 2025–March 2026), Wockhardt's consolidated net profit attributable to shareholders was ₹213 crore, against a loss of ₹47 crore in FY25, on revenue from operations of ₹3,373 crore (up 12.0%).
Wockhardt will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.
On FY26 consolidated figures, against Biocon, Syngene International and Aster DM Healthcare: Wockhardt's operating margin of 12.6% is the second highest of the four (Biocon 8.9%, Syngene International 12.5%, Aster DM Healthcare 13.7%; peer average 11.7%); its return on equity of 4.6% is the third highest of the four (Biocon 1.4%, Syngene International 6.6%, Aster DM Healthcare 9.7%; peer average 5.9%); its revenue growth over three years of 8.4% a year is the second highest of the four (Biocon 14.9% a year, Syngene International 5.4% a year, Aster DM Healthcare −27.0% a year; peer average −2.2% a year).
At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Wockhardt's PE ratio is 146.2, the second highest of the four: Biocon 148.7, Syngene International 50.8 and Aster DM Healthcare 90.7, a peer average of 96.7. Each is the company's market capitalisation at that price divided by its FY26 net profit.
In FY26, Wockhardt earned net profit attributable to shareholders of ₹213 crore on revenue of ₹3,373 crore, against ₹386 crore on ₹16,927 crore for Biocon. Wockhardt's operating margin was 12.6% (Biocon 8.9%) and its return on equity 4.6% (Biocon 1.4%). At the 29 October 2026 close, Wockhardt's market capitalisation was ₹31,151 crore against ₹57,346 crore for Biocon, and its PE ratio on FY26 profit 146.2 against 148.7.
From Wockhardt's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.